Literature DB >> 7681247

Molecular cloning and sequence analysis of cDNA for a 59 kD bone sialoprotein of the rat: demonstration that it is a counterpart of human alpha 2-HS glycoprotein and bovine fetuin.

T Ohnishi1, O Nakamura, M Ozawa, N Arakaki, T Muramatsu, Y Daikuhara.   

Abstract

A complementary DNA (cDNA) for the 59 kD bone sialoprotein, which is supposed to be the rat counterpart of human alpha 2-HS glycoprotein (alpha 2-HSG) and is synthesized by both hepatocytes and osteoblasts, has been cloned from a rat liver cDNA library. Polyclonal rabbit antibodies to rat 59 kD bone sialoprotein were used to identify and isolate the cDNA. The amino acid sequence of 59 kD bone sialoprotein deduced from the cDNA revealed that the entire protein consisted of 352 amino acid residues, including a signal peptide of 18 amino acid residues, and contained three possible N-glycosylation sites. On Northern blot analysis of rat liver, an mRNA of about 1.5 kilobases was detected. An mRNA of 59 kD bone sialoprotein was also detectable in rat bone but not in other tissues, such as kidney, brain, and lung. A computer search of protein and nucleic acid data bases revealed that 68.2, 63.2, and 97.4% amino acid residues of 59 kD bone sialoprotein were identical with those of human alpha 2-HSG, bovine fetuin, and rat phosphorylated N-glycoprotein (pp63), respectively. The positions of cysteine residues in 59 kD bone sialoprotein also completely matched those in human alpha 2-HSG and bovine fetuin, indicating that the sialoprotein is the rat counterpart of human alpha 2-HSG and bovine fetuin. In addition, comparison of the nucleotide sequence of cDNA for rat fetuin/alpha 2-HSG with that for pp63 recently corrected showed only two differences in nucleotides in the entire protein coding regions of the two proteins, and immunoreactive rat fetuin/alpha 2-HSG in the conditioned medium of adult rat hepatocytes in primary culture was found to be phosphorylated. Thus, because rat fetuin/alpha 2-HSG isolated from bone and synthesized by osteoblasts in culture does not contain phosphorus, it seems to be pp63 dephosphorylated during circulation or in the bone matrix.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681247     DOI: 10.1002/jbmr.5650080314

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

Review 1.  Friends and relations of the cystatin superfamily--new members and their evolution.

Authors:  W M Brown; K M Dziegielewska
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

Review 2.  Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition.

Authors:  Anne George; Arthur Veis
Journal:  Chem Rev       Date:  2008-10-03       Impact factor: 60.622

3.  Immunohistochemical localization and mRNA expression of matrix Gla protein and fetuin-A in bone biopsies of hemodialysis patients.

Authors:  Giorgio Coen; Paola Ballanti; Giuliana Silvestrini; Daniela Mantella; Micaela Manni; Salvatore Di Giulio; Stefania Pisanò; Martina Leopizzi; Giuseppe Di Lullo; Ermanno Bonucci
Journal:  Virchows Arch       Date:  2009-01-17       Impact factor: 4.064

Review 4.  Biomineralization of bone: a fresh view of the roles of non-collagenous proteins.

Authors:  Jeffrey Paul Gorski
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01

5.  A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation.

Authors:  Wei Li; Shu Zhu; Jianhua Li; Yan Huang; Rongrong Zhou; Xuegong Fan; Huan Yang; Xing Gong; N Tony Eissa; Willi Jahnen-Dechent; Ping Wang; Kevin J Tracey; Andrew E Sama; Haichao Wang
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

6.  The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.

Authors:  Gurkan Celebi; Halil Genc; Hasan Gurel; Erdim Sertoglu; Muammer Kara; Serkan Tapan; Cengizhan Acikel; Yildirim Karslioglu; Cemal Nuri Ercin; Teoman Dogru
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.